[默克尔细胞癌145例的治疗]
[Management for 145 cases of Merkel cell carcinoma].
作者信息
Assouline A, Tai P, Levy A, Yu E, Dong Lian J, Joseph K, Miale T, Krzisch C
机构信息
Centre hospitalier universitaire d'Amiens, France.
出版信息
Bull Cancer. 2010 Sep;97(9):1061-6. doi: 10.1684/bdc.2010.1166.
PURPOSE
Merkel cell carcinoma (MCC)/primary cutaneous neuroendocrine carcinoma is a rare and aggressive malignant tumor. Optimal therapeutic strategy has not yet been established.
PATIENTS AND METHODS
Management of 145 patients from five centres was analysed. These data included ages, pathological stages, disease sites, histological and treatment details. Cause-specific (CSS) and overall survivals (OS) were analyzed by the Log-rank and Kaplan-Meier methods.
RESULTS
Median age was 78 years (47-95.2). We experienced 37 local, 37 regional and 15 distant relapses. In case of relapse, salvage therapy has been proposed whenever the general state of health condition of patient permitted it.
CONCLUSION
Our results for the treatment of relapse encourage multidisciplinary approach. Multicenter prospective trials are still needed to clarify and validate the optimal strategy.
目的
默克尔细胞癌（MCC）/原发性皮肤神经内分泌癌是一种罕见且侵袭性强的恶性肿瘤。尚未确立最佳治疗策略。
患者与方法
分析了来自五个中心的145例患者的治疗情况。这些数据包括年龄、病理分期、疾病部位、组织学及治疗细节。采用对数秩检验和Kaplan-Meier法分析特异性病因生存率（CSS）和总生存率（OS）。
结果
中位年龄为78岁（47 - 95.2岁）。我们观察到37例局部复发、37例区域复发和15例远处复发。复发时，只要患者的一般健康状况允许，就建议进行挽救治疗。
结论
我们对复发治疗的结果鼓励采用多学科方法。仍需要多中心前瞻性试验来阐明和验证最佳策略。
Zotero 插件